【摘要】 目的:评价慢性阻塞性肺疾病急性加重期应用门冬氨酸钾镁治疗的临床疗效和安全性。方法:将入选的98例慢性阻塞性肺疾病急性加重期患者进行前瞻性、开放的、随机对照临床试验。在常规治疗基础上,观察组(51例)给予门冬氨酸钾镁治疗,对照组(47例)不予门冬氨酸钾镁治疗;观察其对心、肺功能恢复的影响、并发症的发生率及死亡率情况。结果:观察组总有效率明显高于对照组(P<0.01)。结论:慢性阻塞性肺疾病急性加重期时应用门冬氨酸钾镁治疗可明显缩短病程、改善预后,门冬氨酸钾镁可作为治疗慢性阻塞性肺疾病急性加重期的联合用药。更多还原

【Abstract】 Objective:To evaluate the clinical curative effect and safety of potassium magnesium aspartate used in the treatment of acute exacerbations of chronic obstructive pulmonary disease(AECOPD).Methods:Prospective and open,randomized and controlled trials were applied to 98 AECOPD patients. The treatment group (51 cases) were treated with potassium magnesium aspartate on the basis of conventional treatment, the control group (47 cases) were received basic therapy. The effect on the recovery of cardiac,pulmonary function as well as incidence of deuteropathy and death rate were observed. Results:The improvement rate in the treatment group was higher than that of the control group (P<0.01).Conclusion:The treatment of AECOPD by using potassium magnesium aspartate can obviously improve the results of prognosis.Potassium magnesium aspartate turns out to be conventional drug for treatment of AECOPD.更多还原